Protocol Ledger

NCT06904248 · Phase III · COMPLETED

Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-severe Pain Following Abdominal Surgery

Interventional Phase III clinical trial protocol NCT06904248 sponsored by Yangtze River Pharmaceutical Group Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-01-29 Enrollment: 224 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06904248
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)224 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06904248
Protocol FieldVerified Registry Value
NCT IdentifierNCT06904248
Consolidated Lead SponsorYangtze River Pharmaceutical Group Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment224 participants (ACTUAL)
Registered Start Date2024-01-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06904248
Hospital Research SiteLocationSite Profile
The Third Xiangya Hospital of Central South UniversityChangsha, ChinaOpen Hospital Dossier ->
The Second Hospital of Anhui Medical UniversityHefei, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI